Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
Wolinsky, Jerry SDepartment of Neurology, The University of Texas Health Science Center at Houston, USA
Narayana, Ponnada ADepartment of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, USA
Nelson, FlaviaDepartment of Neurology, The University of Texas Health Science Center at Houston, USA
Datta, SushmitaDepartment of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, USA
O’Connor, PaulSt Michael’s Hospital, University of Toronto, Canada
Confavreux, ChristianService de Neurologie A, Hospices Civils de Lyon; Université Claude Bernard Lyon 1, France
Comi, GiancarloDepartment of Neurology and Institute of Experimental Neurology, San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy
Kappos, LudwigDepartment of Neurology, University Hospital Basel, Switzerland
Olsson, Tomas PDepartment of Clinical Neuroscience, Karolinska Institute, Sweden
EnglishObjective: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). Methods: Patients ( n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. Results: After 108 weeks, increase in total lesion volume was 67.4% ( p=0.0003) and 39.4% ( p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. Conclusions: Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.